Late Stage Chronic Kidney Disease Drugs Market to Grow at a CAGR of 11.6% to reach US$ 11,096.9 Million from 2020 to 2027

    Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography

    Publication Month: Sep 2020 | Report Code: TIPRE00013768 | No. of Pages: 194 | Category: Pharmaceuticals | Status: Published

    The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% from 2020 to 2027.

    Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage, the kidney loses all its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life. High prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are the major factor propelling the market growth. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

    Lucrative Regions for Late Stage Chronic Kidney Disease Drugs Market
    Lucrative Regions for Late Stage Chronic Kidney Disease Drugs Market

    Get more information on this report :



    Market Insights

    High Prevalence of Diseases Leading to Chronic Kidney Diseases

    Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer's press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.

    According to the CDC, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association (ADA). According to the CDC, in 2014, around 118,000 people in the US have started the treatment for end-stage renal disease, and the number of people for treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the late stage of chronic kidney disease drugs. These factors are expected to enhance market growth during the forecast period.

    As per the National Kidney Foundation Inc., chronic kidney disease causes more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. It affects an estimated 26 million people in the US (15% of the adult population; more than 1 in 7 adults). 1 in 3 American adults (about 80 million people) is at risk due to CKD. CKD is more common in women than in men. It is the 9th leading cause of death in the US. Glomerulonephritis (diseases that damage the kidney's filtering units); inherited diseases, such as polycystic kidney disease; malformations during the development of fetus; lupus and other immune diseases; obstructions such as kidney stones or an enlarged prostate; and repeated urinary tract infections are among the other conditions that can lead to ESKD.

    Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development

    Manufactures are in a stronger position than ever before to look for targets and treatments and now they have a deeper molecular understanding of CKD. Various manufacturers are investing in the development of sophisticated models that mimic the human kidney accurately than has ever previously been possible. It is impossible to virtually imitate the functions of kidney in classical in vitro systems, while in vivo models; it is intensive to produce, and not always adaptable to human systems. 3D bioprinting and organs-on-chips are the new model systems that the manufacturers in the market are embedding into their research pipeline to bridge this gap. With these groundbreaking techniques, they can test compound behavior and hope to understand disease mechanisms in a subtle way.

    Organs-on-Chip technology provides environments that emulate major aspects of the real kidney physiology; including fluidic channels that are lined with living cells in the accurate structural design. The flow represents the flow of blood carrying nutrients, takes away waste products, and also creates mechanical forces, all critical factors for the functioning of the kidney.

    In 2018, Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to drive in its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization. As part of the agreement, Emulate plans to co-locate scientists within AstraZeneca’s laboratories. The aim of this agreement is to speed up the development of Organs-on-Chips technology and testing within the context of a pharmaceutical organization. Further, in March 2020, the company announced that it has completed the 150th installation of its Zoë instrument, part of a lab-ready platform for Organs-on-Chips technology for use by researchers across various industries. Additionally, the limited number of treatment options for kidney patients is strongly linked to the lack of translatable systems as there is a high attrition rate with kidney candidate drugs in clinical trials. Organs-on-Chip technology could help solve this challenge.

    Product Type-Based Insights

    Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Calcimimetics are commonly used in patients on dialysis to treat secondary hyperparathyroidism. Mineral and bone disorders (MBD) are the common complications of chronic kidney disease (CKD), which are significant risk factors in mortality in CKD patients. Cinacalcet, the only available calcimimetic, is a useful therapeutic in CKD-MBD. Various clinical trials with cinacalcet in hemodialysis patients with SHPT have shown a reduction in parathyroid hormone, phosphate (P), calcium (Ca), and Ca x P product levels more tremendous success in reaching therapeutic goals as per the recommendations of international guidelines. Additionally, some studies have shown that cinacalcet may improve other aspects of CKD-MBD, and reduces the risk of parathyroidectomy and vascular calcification, among others. Secondary hyperparathyroidism (SHPT) is a highly prevalent and crucial complication in patients with chronic kidney disease (CKD). Calcimimetic agents may help control SHPT and achieve the though mineral metabolism targets in patients with late stage chronic kidney disease.

    Calcimimetics act by suppressing the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. calcimimetics in combination with a higher dose of a calcium-based oral phosphate binder is an effective and well-tolerated alternative for the standard treatments such as vitamin D derivatives in combination with a non-calcium-based oral phosphate binder.

    For instance, in February 2017, Amgen received the approval for Parsabiv: an etelcalcetide from US Food and Drug Administration (FDA), for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.

    Global Late Stage Chronic Kidney Disease Drugs Market, by Product Type– 2019 & 2027
    Global Late Stage Chronic Kidney Disease Drugs Market, by Product Type– 2019 & 2027

    Get more information on this report :



    Indication-Based Insights

    Based on indication, the late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. End-stage renal disease (ESRD) patients are at high risk for hyperkalemia, especially when other factors and comorbidities that interfere with renal potassium excretion are present. The prevalence of hyperkalemia in CKD patients is considerably higher than in the general population. Chronic hyperkalemia is a major concern in ESRD patients, especially for those who administer RAAS blockades for cardiac disease and/or diabetes. Potassium binding agents are useful in maintaining the serum potassium in the normal range without lowering the dose or discontinuing RAAS inhibitors and restricting the intake of vegetables and fruits.

    Strategic Insights

    Product launches and expansion strategies are commonly adopted by the companies to expand their footprint worldwide, meet the growing demand, and increase its product portfolio.

    The key players operating in the late stage chronic kidney disease drugs market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

    By Product Type

    • Calcimimetics
    • Vitamin D
    • Sterols
    • Potassium Binders
    • Calcium-Based Phosphate Binders

    By Indication

    • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
    • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
    • Late Stage Chronic Kidney Disease Induced Hyperkalaemia

    By Distribution Channel

    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies

    By Geography

    • North America
      • US
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • UK
      • Spain
    • Asia Pacific (APAC)
      • China
      • India
      • South Korea
      • Japan
      • Australia
    • Middle East & Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE
    • South and Central America (SCAM)
      • Brazil
      • Argentina

    Company Profiles

    • Abbvie Inc.
    • Amgen
    • Astrazeneca
    • Sanofi S.A.
    • Kyowa Kirin Co., Ltd
    • Takeda Pharmaceutical Company Limited
    • Astellas Pharma Inc.
    • Bayer Ag
    • Vifor Pharma Management Ltd.
    • Akebia Therapeutics, Inc.

    1. Introduction

    1.1 Scope of the Study

    1.2 The Insight Partners Research Report Guidance

    1.3 Market Segmentation

    1.3.1 Late Stage Chronic Kidney Disease Drugs Market – By Product Type

    1.3.2 Late Stage Chronic Kidney Disease Drugs Market – By Indication

    1.3.3 Late Stage Chronic Kidney Disease Drugs Market – By Distribution Channel

    1.3.4 Late Stage Chronic Kidney Disease Drugs Market – By Geography

    2. Late Stage Chronic Kidney Disease Drugs Market – Key Takeaways

    3. Research Methodology

    3.1 Coverage

    3.2 Secondary Research

    3.3 Primary Research

    4. Late Stage Chronic Kidney Disease Drugs Market – Market Landscape

    4.1 Overview

    4.2 PEST Analysis

    4.2.1 North America – PEST Analysis

    4.2.2 Europe – PEST Analysis

    4.2.3 Asia-Pacific – PEST Analysis

    4.2.4 Middle East and Africa (MEA) – PEST Analysis

    4.2.5 South & Central America (SCAM) – PEST Analysis

    4.3 Expert Opinion

    5. Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics

    5.1 Market Drivers

    5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases

    5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs

    5.2 Market Restraints

    5.2.1 Delay in the Diagnosis of Chronic Kidney Disease

    5.3 Market Opportunities

    5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs

    5.4 Future Trends

    5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development

    5.5 Impact Analysis

    6. Late Stage Chronic Kidney Disease Drugs Market – Global Analysis

    6.1 Global Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast And Analysis

    6.2 Global Late Stage Chronic Kidney Disease Drugs Market, By Geography - Forecast And Analysis

    6.3 Market Positioning of Key Players

    7. Late Stage Chronic Kidney Disease Drugs Market Analysis – By Product Type

    7.1 Overview

    7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)

    7.3 Calcimimetics

    7.3.1 Overview

    7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    7.4 Vitamin D

    7.4.1 Overview

    7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    7.5 Potassium Binders

    7.5.1 Overview

    7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    7.6 Calcium-Based Phosphate Binders

    7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    7.7 Others

    7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    8. Late Stage Chronic Kidney Disease Drugs Market Analysis By Indication

    8.1 Overview

    8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)

    8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism

    8.3.1 Overview

    8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia

    8.4.1 Overview

    8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia

    8.5.1 Overview

    8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    9. Late Stage Chronic Kidney Disease Drugs Market Analysis By Distribution Channel

    9.1 Overview

    9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)

    9.3 Hospital Pharmacies

    9.3.1 Overview

    9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    9.4 Online Pharmacies

    9.4.1 Overview

    9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    9.5 Retail Pharmacies

    9.5.1 Overview

    9.5.2 Retail Pharmacies Segment : Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    10. Late Stage Chronic Kidney Disease Drugs Market Analysis And Forecasts To 2027 – Geographical Analysis

    10.1 North America: Late Stage Chronic Kidney Disease Drugs Market

    10.1.1 Overview

    10.1.2 North America: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.3 North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.1.4 North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.1.5 North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.1.6 North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    10.1.7 US: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.7.1 US: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.7.2 US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.1.7.3 US: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.1.7.4 US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.1.8 Canada: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.8.1 Canada: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.8.2 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.1.8.3 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.1.8.4 Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.1.9 Mexico: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.9.1 Mexico: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.1.9.2 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.1.9.3 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.1.9.4 Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2 Europe: Late Stage Chronic Kidney Disease Drugs Market

    10.2.1 Overview

    10.2.2 Europe: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.3 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.4 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.5 Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2.6 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    10.2.7 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.7.1 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.7.2 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.7.3 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.7.4 Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2.8 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.8.1 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.8.2 France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.8.3 France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.8.4 France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2.9 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.9.1 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.9.2 UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.9.3 UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.9.4 UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2.10 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.10.1 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.10.2 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.10.3 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.10.4 Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.2.11 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.11.1 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.2.11.2 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.2.11.3 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.2.11.4 Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.3 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market

    10.3.1 Overview

    10.3.2 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)

    10.3.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.3.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.3.5 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.3.6 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    10.4.1 China: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.1.1 China: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.1.2 China Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.4.1.3 China Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.4.1.4 China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.4.2 Japan: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.2.1 Japan: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.2.2 Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.4.2.3 Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.4.2.4 Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.4.3 India: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.3.1 India: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.3.2 India Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.4.3.3 India Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.4.3.4 India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.4.4 South Korea: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.4.1 South Korea: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.4.2 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.4.4.3 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.4.4.4 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.4.5 Australia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.5.1 Australia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.4.5.2 Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.4.5.3 Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.4.5.4 Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    10.5 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market

    10.5.1 Overview

    10.5.2 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

    10.5.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    10.5.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication– Revenue and Forecast to 2027 (USD Million)

    10.5.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.5.6 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)

    10.5.7 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.7.1 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.7.2 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.5.7.3 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.5.7.4 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.5.8 UAE: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.8.1 UAE: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.8.2 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    10.5.8.3 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    10.5.8.4 UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.5.9 South Africa: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.9.1 South Africa: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.5.9.2 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.5.9.3 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.5.9.4 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market

    10.6.1 Overview

    10.6.2 South and Central America: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.6.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.6.4 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.6.5 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.6.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    10.6.7 Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.6.7.1 Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.6.7.2 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    10.6.7.3 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication– Revenue and Forecast to 2027 (USD Million)

    10.6.7.4 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    10.6.8 Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.6.8.1 Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    10.6.8.2 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    10.6.8.3 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    10.6.8.4 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    11. Impact of COVID-19 Pandemic on Global Late Stage Chronic Kidney Disease Drugs Market

    11.1 North America: Impact Assessment of COVID-19 Pandemic

    11.2 Europe: Impact Assessment of COVID-19 Pandemic

    11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

    11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

    12. Late Stage Chronic Kidney Disease Drugs Market – Industry Landscape

    12.1 Overview

    12.2 Growth Strategies Done by the Companies in the Market, (%)

    12.3 Organic Developments

    12.3.1 Overview

    12.4 Inorganic Developments

    12.4.1 Overview

    13. Company Profiles

    13.1 AbbVie Inc.

    13.1.1 Key Facts

    13.1.2 Business Description

    13.1.3 Products and Services

    13.1.4 Financial Overview

    13.1.5 SWOT Analysis

    13.1.6 Key Developments

    13.2 Amgen

    13.2.1 Key Facts

    13.2.2 Business Description

    13.2.3 Products and Services

    13.2.4 Financial Overview

    13.2.5 SWOT Analysis

    13.2.6 Key Developments

    13.3 AstraZeneca

    13.3.1 Key Facts

    13.3.2 Business Description

    13.3.3 Products and Services

    13.3.4 Financial Overview

    13.3.5 SWOT Analysis

    13.3.6 Key Developments

    13.4 Sanofi

    13.4.1 Key Facts

    13.4.2 Business Description

    13.4.3 Products and Services

    13.4.4 Financial Overview

    13.4.5 SWOT Analysis

    13.4.6 Key Developments

    13.5 Kyowa Kirin Co., Ltd

    13.5.1 Key Facts

    13.5.2 Business Description

    13.5.3 Products and Services

    13.5.4 Financial Overview

    13.5.5 SWOT Analysis

    13.5.6 Key Developments

    13.6 Takeda Pharmaceutical Company Limited

    13.6.1 Key Facts

    13.6.2 Business Description

    13.6.3 Products and Services

    13.6.4 Financial Overview

    13.6.5 SWOT Analysis

    13.6.6 Key Developments

    13.7 Astellas Pharma Inc.

    13.7.1 Key Facts

    13.7.2 Business Description

    13.7.3 Products and Services

    13.7.4 Financial Overview

    13.7.5 SWOT Analysis

    13.7.6 Key Developments

    13.8 Bayer AG

    13.8.1 Key Facts

    13.8.2 Business Description

    13.8.3 Products and Services

    13.8.4 Financial Overview

    13.8.5 SWOT Analysis

    13.8.6 Key Developments

    13.9 Vifor Pharma Management Ltd.

    13.9.1 Key Facts

    13.9.2 Business Description

    13.9.3 Products and Services

    13.9.4 Financial Overview

    13.9.5 SWOT Analysis

    13.9.6 Key Developments

    13.10 Akebia Therapeutics, Inc.

    13.10.1 Key Facts

    13.10.2 Business Description

    13.10.3 Products and Services

    13.10.4 Financial Overview

    13.10.5 SWOT Analysis

    13.10.6 Key Developments

    14. Appendix

    14.1 Glossary of Terms

    LIST OF TABLES

    Table 1. North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 2. North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 3. North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 4. US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 5. US: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 6. US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 7. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 8. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 9. Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 10. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 11. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 12. Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 13. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 14. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 15. Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 16. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 17. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 18. Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 19. France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 20. France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 21. France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 22. UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 23. UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 24. UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 25. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 26. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 27. Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 28. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 29. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 30. Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 31. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 32. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 33. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 34. China Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 35. China Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 36. China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 37. Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 38. Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 39. Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 40. India Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 41. India Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 42. India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 43. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 44. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 45. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 46. Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 47. Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 48. Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

    Table 49. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    Table 50. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication– Revenue and Forecast to 2027 (USD Million)

    Table 51. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    Table 52. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 53. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 54. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    Table 55. UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

    Table 56. UAE Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 57. UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    Table 58. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 59. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 60. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel– Revenue and Forecast to 2027(USD Million)

    Table 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 62. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 63. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel– Revenue and Forecast to 2027(USD Million)

    Table 64. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 65. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 66. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    Table 67. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

    Table 68. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

    Table 69. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

    Table 70. Organic Developments Done By Companies

    Table 71. Inorganic Developments Done by Companies

    Table 72. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market

    LIST OF FIGURES

    Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation

    Figure 2. Late Stage Chronic Kidney Disease Drugs Market – By Geography

    Figure 3. Global Late Stage Chronic Kidney Disease Drugs Market Overview

    Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market

    Figure 5. Asia-Pacific to Show Remarkable Growth During Forecast Period

    Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market, By Geography (US$ Million)

    Figure 7. Global Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)

    Figure 8. Global Late Stage Chronic Kidney Disease Drugs Market, Industry Landscape

    Figure 9. North America PEST Analysis

    Figure 10. Europe PEST Analysis

    Figure 11. Asia-Pacific PEST Analysis

    Figure 12. Middle East and Africa (MEA) PEST Analysis

    Figure 13. South & Central America (SCAM) PEST Analysis

    Figure 14. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints

    Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market – Revenue Forecast And Analysis – 2019- 2027

    Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market – By Geography Forecast and Analysis – 2019- 2027

    Figure 17. Market Positioning of Key Players

    Figure 18. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)

    Figure 19. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 20. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 21. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 22. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 23. Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 24. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)

    Figure 25. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 26. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 27. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 28. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)

    Figure 29. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 30. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 31. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 32. North America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

    Figure 33. North America: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

    Figure 34. North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    Figure 35. US: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 36. Canada: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 37. Mexico: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 38. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

    Figure 39. Europe: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

    Figure 40. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    Figure 41. Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 42. France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 43. UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 44. Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 45. Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 46. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

    Figure 47. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

    Figure 48. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    Figure 49. China: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 50. Japan: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 51. India: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 52. South Korea: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 53. Australia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 54. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

    Figure 55. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

    Figure 56. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)

    Figure 57. Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 58. UAE: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 59. South Africa: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 60. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

    Figure 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

    Figure 62. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

    Figure 63. Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 64. Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

    Figure 65. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In North American Countries

    Figure 66. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In European Countries

    Figure 67. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In Asia Pacific Countries

    Figure 68. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in Rest of the World

    Figure 69. Growth Strategies Done by the Companies in the Market, (%)

    The List of Companies - Late Stage Chronic Kidney Disease Drugs Market

    1. AbbVie Inc.
    2. Amgen
    3. AstraZeneca
    4. Sanofi
    5. Kyowa Kirin Co., Ltd.
    6. Takeda Pharmaceutical Company Limited
    7. Astellas Pharma Inc.
    8. Bayer AG
    9. Vifor Pharma Management Ltd.
    10. Akebia Drugs, Inc.
    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the late stage chronic kidney disease drugs market.

     

    • Highlights key business priorities in order to assist companies to realign their business strategies.

     

    • The key findings and recommendations highlight crucial progressive industry trends in the global late stage chronic kidney disease drugs market, thereby allowing players across the value chain to develop effective long-term strategies.

     

    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

     

    • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

     

    • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
    TIPRE00013768
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market



    Frequently Asked Questions

    Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage of kidney disease, the kidneys have lost nearly all their ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Few classes of drugs are specifically used for the treatment of late stage chronic kidney disease are known as late stage chronic kidney disease drugs.
    The factors that are driving growth of the market are high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are expected to boost the growth of the global late stage chronic kidney disease drugs market.
    The late stage chronic kidney disease drugs market majorly consists of the players such AbbVie Inc., Amgen, AstraZeneca, Sanofi, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bayer AG, Vifor Pharma Management Ltd., and Akebia Drugs, Inc. among others.

    Pricing
    • $2000
    • $4500 $3640
    • $4500 $5240
    • $4500 $6840

        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount   Speak to Analyst